OBJECTIVES: Docetaxel is considered first-line chemotherapy for patients with metastatic
castrate resistant prostate cancer (CRPC). Carboplatin and paclitaxel have demonstrated …

5148 Background: Docetaxel has a survival benefit in CRPC. Oral and IV platinum
derivatives have activity in CRPC. We hypothesized that a novel combination of docetaxel …

Background: Treatment with docetaxel in combination with prednisone is the standard first-
line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). For …

Objectives: Management of castration-resistant prostate cancer after docetaxel has become
an unmet need for which various agents have been investigated. We report our experience …

Purpose To assess the efficacy and safety of docetaxel rechallenge in the salvage setting in
metastatic castration-resistant prostate cancer (mCRPC) patients. Materials and Methods …

e15020 Background: In 2004 docetaxel was approved and has become the standard of care
in first-line for metastatic CRPC. The optimal treatment duration with docetaxel is not known …

Background Docetaxel is standard first-line chemotherapy for patients with metastatic
castration–resistant prostate carcinoma (mCRPC). Docetaxel re-challenge has never been …

Background There is no proven, effective, standard second-line chemotherapy for castration-
and docetaxel-resistant prostate cancer (DRPC). Recent data suggest that carboplatin may …

Background Docetaxel represents the first-line treatment for castration-resistant prostate
cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in …

BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among
men in the US To the authors' knowledge, there is no proven, effective, second‐line therapy …